- Home
- LAB vs MREO Comparison
LAB vs MREO Comparison
Compare LAB & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAB
- MREO
- Stock Information
- Founded
- LAB 1999
- MREO 2015
- Country
- LAB United States
- MREO United Kingdom
- Employees
- LAB N/A
- MREO N/A
- Industry
- LAB Biotechnology: Laboratory Analytical Instruments
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- LAB Industrials
- MREO Health Care
- Exchange
- LAB Nasdaq
- MREO Nasdaq
- Market Cap
- LAB 473.2M
- MREO 438.8M
- IPO Year
- LAB 2011
- MREO N/A
- Fundamental
- Price
- LAB $1.23
- MREO $1.74
- Analyst Decision
- LAB Buy
- MREO Strong Buy
- Analyst Count
- LAB 2
- MREO 5
- Target Price
- LAB $2.50
- MREO $7.20
- AVG Volume (30 Days)
- LAB 1.4M
- MREO 1.8M
- Earning Date
- LAB 08-11-2025
- MREO 08-12-2025
- Dividend Yield
- LAB N/A
- MREO N/A
- EPS Growth
- LAB N/A
- MREO N/A
- EPS
- LAB N/A
- MREO N/A
- Revenue
- LAB $172,271,000.00
- MREO $500,000.00
- Revenue This Year
- LAB N/A
- MREO N/A
- Revenue Next Year
- LAB $12.18
- MREO $38.38
- P/E Ratio
- LAB N/A
- MREO N/A
- Revenue Growth
- LAB 26.39
- MREO N/A
- 52 Week Low
- LAB $0.92
- MREO $1.47
- 52 Week High
- LAB $2.32
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- LAB 43.04
- MREO 44.98
- Support Level
- LAB $1.15
- MREO $1.64
- Resistance Level
- LAB $1.37
- MREO $1.78
- Average True Range (ATR)
- LAB 0.07
- MREO 0.09
- MACD
- LAB -0.02
- MREO 0.04
- Stochastic Oscillator
- LAB 26.67
- MREO 87.10
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).